PREVENT HAZARDOUS DRUG EXPOSURE.

View NCGA Bill Details2013-2014 Session
House Bill 644 (Public) Filed Tuesday, April 9, 2013
A BILL TO BE ENTITLED AN ACT RELATING TO THE HANDLING OF ANTINEOPLASTIC AGENTS TO PREVENT DISEASE AND INJURY CAUSED BY EXPOSURE.
Intro. by Fulghum, Murry, Carney.

Status: Ch. SL 2014-76 (House Action) (Jul 22 2014)

SOG comments (1):

Long title change

The Senate committee substitute to the 2nd edition change the act's long title. The previous long title was: A BILL TO BE ENTITLED AN ACT RELATING TO THE HANDLING OF HAZARDOUS DRUGS TO PREVENT DISEASE AND INJURY CAUSED BY EXPOSURE.

H 644/S.L. 2014-76

Bill Summaries:

  • Summary date: Jul 22 2014 - More information

    AN ACT RELATING TO THE HANDLING OF ANTINEOPLASTIC AGENTS TO PREVENT DISEASE AND INJURY CAUSED BY EXPOSURE. Enacted July 22, 2014. Effective July 22, 2014.

     

  • Summary date: Jul 15 2014 - More information

    Senate committee substitute makes the following changes to the 2nd edition.

    Amends GS 95-127 (Definitions) to remove the definitions forantineoplastic drugand andhazardous drugsadded in the previous edition to the Occupational Safety and Health Act of North Carolina (OSHA). Adds a definition to OSHA forantineoplastic agent, defined as a chemotherapy drug or cytotoxic drug used to treat cancer patients and some non-cancer patients. Also amends the "whereas clauses" to conform to the changes to GS 95-127.

    Amends proposed GS 95-156 to direct the Commissioner of Labor to adopt rules establishing requirements for handling antineoplastic agents in facilities where there is occupational exposure to those agents (was, establish requirements for the handling of antineoplastic and other hazardous drugs in health care facilities). Requires that the rules must be consistent with, but not exceed, recommendations issued by theNational Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) in the publication NIOSHAlert: Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs inHealth CareSettings,as published in 2004, including subsequent editions and amendments.

    Deletes provision that rules adopted under this section do not apply to an entity accredited by the Joint Commission on Accreditation ofHealthcareOrganizations or otherrecognized hospital accreditation body that has filed certain documentation regarding the accreditation process with the Department of Labor.

    Directs the Commissioner of Labor to adopt rules to implement this act no later than January 1, 2016 (was, January 1, 2015). Provides that the rules adopted under this section are not subject to GS 150B-19.1(e), GS 150B-19.1(f), GS 150B-19.1(h), and GS 150B-21.4. Requires the Commissioner to establish an advisory workgroup that includes hospitals, organizations representing health care personnel, and other interested stakeholders to develop the rules required by this act.

    Amends the long title to reflect changes to the bill content.


  • Summary date: May 14 2013 - More information

    House committee substitute makes the following changes to the 1st edition.

    Amends GS 95-127, toadd definitions for the terms antineoplastic drug and hazardous drugsto GS Chapter 95, Article 16, the Occupational Safety and Health Act of North Carolina (OSHA). Removes the definitions for these terms from GS 95-174 (Article 18, Hazardous Chemicals Right to Know Act). Makes additional technicaland organizational changes toGS 95-127.

    Makes technical changes to GS 94-133(a).

    Recodifies proposed GS 95-199 in Article 18, Handling of dangerous drugs, as new GS 95-156 in Article 16. Makes organizational changes but substantively retains the provisionsdirecting the Commissioner of Labor to adopt rules toimplement this act no later than January 1, 2015.


  • Summary date: Apr 9 2013 - More information

    Amends GS 95-174, the definitions section of the Hazardous Chemicals Right to Know Act, by adding two new terms and definitions, antineoplastic drug and hazardous drugs.

    Enacts new GS 95-199 (Handling of dangerous drugs), providing that the Commissioner of Labor (Commissioner) must adopt rule requirements by January 1, 2015, for the handling of antineoplastic and other hazardous drugs in health care facilities. Rulemaking must consider input from a variety of stakeholders, including hospitals.  Rules adopted must be consistent with and not exceed provisions adopted by the National Institute for Occupational Safety and Health alert on the dangers of exposures to antineoplastic and other hazardous drugs in health care facilities. The Commissioner will investigate complaints and enforce these requirements in accordance with the provisions of this Part.


Printer-friendly: Click to view